---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-041308"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2023-12-12T23:59:59+00:00"
generated_at: "2026-06-07T14:28:52.753379+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology Q2 revenue $11.6M (-19% YoY); revises FY2024 guidance to flat

## Summary
- Operating loss of $2.0M vs $7K income a year ago; adjusted EBITDA loss of $1.4M.
- Gross margin fell to 42.8% from 47.9% on lower revenue and fixed costs.
- FY2024 revenue guidance revised to be generally flat YoY, citing customer cancellations.
- Hired Brady Davis as President to lead new strategic initiatives.
- Corellia AI drug discovery advancing with two lead targets; seeking capital.

## SEC filing metadata
- accession: 0001628280-23-041308
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2023-12-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828023041308/0001628280-23-041308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828023041308/csbr-20231212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-041308
- JSON: https://secwatch.observer/filing/0001628280-23-041308.json
- Plain text: https://secwatch.observer/filing/0001628280-23-041308.txt

## Key facts
- Earnings Releases
  CHAMPIONS ONCOLOGY, INC. reported first six months of fiscal 2024 results: revenue $24.1 million.
  - Period: first six months of fiscal 2024
  - Revenue: $24.1 million
  - Result: reported results
  source text: For the first six months of fiscal 2024, revenue decreased 13.9% to $24.1 million compared to $28.0 million for the first six months of fiscal 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/771856/000162828023041308/0001628280-23-041308-index.htm
- Earnings Releases
  CHAMPIONS ONCOLOGY, INC. reported its second quarter of fiscal 2024, ended October 31, 2023 results: revenue $11.6 million. Guidance lowered.
  - Period: its second quarter of fiscal 2024, ended October 31, 2023
  - Revenue: $11.6 million
  - Guidance: lowered
  - Result: reported results
  source text: Champions Oncology Reports Quarterly Revenue of $11.6 Million
  evidence_url: https://www.sec.gov/Archives/edgar/data/771856/000162828023041308/0001628280-23-041308-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.